Eucon 50 mg/2 ml (IM/IV Injection)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Pacific pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particulary obstetric patients
Pharmacology
Competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Dosage & Administration
- 150 mg twice daily for duodenal and gastric ulcer
- 150 mg twice daily for reflux oesophagitis
- 150 mg 3 times daily for Zollinger Ellison syndrome
- 150 mg twice daily for episodic dyspepsia
- 150 mg at night for maintenance
- 2-4 mg/kg twice daily for children peptic ulcer
- Ranitidine injection may be given intravenously or intramuscularly at different dosages based on condition and age
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide. Minimally inhibits hepatic metabolism of certain drugs. May alter absorption of pH-dependent drugs and reduce bioavailability with antacids.
Contraindications
Hypersensitivity to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
Ranitidine crosses the placenta. Caution advised during pregnancy and lactation.
Precautions & Warnings
Should be given in reduced dosage to patients with impaired renal and hepatic function.
Use in Special Populations
Ulcer healing rates found similar in elderly patients. No difference in adverse effects incidence.
Overdose Effects
Specific in action, no particular problems expected. Symptomatic and supportive therapy recommended.
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Dilution guidelines for slow IV inj, intermittent slow IV infusion, and continuous IV infusion based on condition
Storage Conditions
Cool, dry place; protect from light